

## Dr. Antoine Leimgruber

Director of Nuclear Medicine Development, Swiss Medical Network & Expert in Theranostics

Dr. Antoine Leimgruber is the Director of Nuclear Medicine Development for Swiss Medical Network, overseeing the advancement of molecular imaging and theranostic programs across its network, including Clinique de Genolier. He is an FMH specialist in Nuclear Medicine and Radiology, with a strong background in physics (MSc from EPFL) and extensive clinical and research experience in hybrid imaging and personalized cancer diagnostics.

At the Genolier Innovation Hub, Dr. Leimgruber spearheads the integration of precision medicine, notably through theranostics, a cutting-edge approach that combines targeted imaging and therapy, enabled by PET and SPECT technologies. His expertise extends to reducing radiation exposure via ultra-low dose PET imaging protocols and applying artificial intelligence to distill complex imaging data into actionable clinical insights.

Combining clinical leadership, technological innovation, and scientific rigor, Dr. Leimgruber is a driving force for translating breakthrough imaging technologies into real-world oncology solutions, at the intersection of precision care, research and patient-centered innovation.